Karyopharm Therapeutics Inc. (KPTI) Given a $18.00 Price Target by Canaccord Genuity Analysts

Canaccord Genuity set a $18.00 target price on Karyopharm Therapeutics Inc. (NASDAQ:KPTI) in a research note released on Tuesday, August 8th. The brokerage currently has a buy rating on the stock.

Several other equities analysts also recently issued reports on the stock. BidaskClub downgraded shares of Karyopharm Therapeutics from a sell rating to a strong sell rating in a research note on Monday, July 31st. Zacks Investment Research downgraded shares of Karyopharm Therapeutics from a buy rating to a hold rating in a research note on Tuesday, July 18th. Jefferies Group LLC reiterated a buy rating and set a $16.00 target price on shares of Karyopharm Therapeutics in a research note on Friday, July 14th. Robert W. Baird reiterated an outperform rating and set a $15.00 target price on shares of Karyopharm Therapeutics in a research note on Tuesday, July 4th. Finally, Cantor Fitzgerald set a $18.00 target price on shares of Karyopharm Therapeutics and gave the stock a buy rating in a research note on Saturday, June 24th. Two research analysts have rated the stock with a sell rating, one has given a hold rating, seven have given a buy rating and one has given a strong buy rating to the stock. Karyopharm Therapeutics presently has an average rating of Buy and an average price target of $14.56.

Shares of Karyopharm Therapeutics (NASDAQ KPTI) traded up 0.74% during trading on Tuesday, reaching $8.21. The company’s stock had a trading volume of 107,618 shares. The company has a 50 day moving average of $8.95 and a 200-day moving average of $9.94. The stock’s market cap is $387.00 million. Karyopharm Therapeutics has a 12-month low of $6.27 and a 12-month high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings data on Tuesday, August 8th. The company reported ($0.64) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.64). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 70.42%. During the same period in the prior year, the firm earned ($0.84) earnings per share. The firm’s revenue was down 95.0% on a year-over-year basis. Analysts forecast that Karyopharm Therapeutics will post ($2.69) EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was published by BNB Daily and is the sole property of of BNB Daily. If you are accessing this piece on another website, it was illegally copied and reposted in violation of international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.baseball-news-blog.com/2017/08/19/karyopharm-therapeutics-inc-kpti-receives-buy-rating-from-canaccord-genuity-updated.html.

Several hedge funds and other institutional investors have recently modified their holdings of KPTI. Vanguard Group Inc. boosted its position in shares of Karyopharm Therapeutics by 31.1% in the second quarter. Vanguard Group Inc. now owns 1,621,420 shares of the company’s stock worth $14,675,000 after buying an additional 384,658 shares during the period. Teachers Advisors LLC raised its position in shares of Karyopharm Therapeutics by 915.0% in the first quarter. Teachers Advisors LLC now owns 420,563 shares of the company’s stock worth $5,400,000 after buying an additional 379,127 shares during the period. Iguana Healthcare Management LLC bought a new position in shares of Karyopharm Therapeutics during the first quarter worth $3,531,000. EAM Investors LLC bought a new position in shares of Karyopharm Therapeutics during the first quarter worth $3,462,000. Finally, Candriam Luxembourg S.C.A. raised its position in shares of Karyopharm Therapeutics by 154.7% in the second quarter. Candriam Luxembourg S.C.A. now owns 438,000 shares of the company’s stock worth $3,964,000 after buying an additional 266,000 shares during the period. 57.58% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Analyst Recommendations for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply